Search research articles
Contact Us
Filters
Showing results (71-80 of 76) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 76 results.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
The Journal of Molecular Diagnostics : JMD
|
February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih, Robin D Harrington, David J Sims, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
Cancer Cell
|
November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Linda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 76) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 76 results.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
The Journal of Molecular Diagnostics : JMD
|
February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih, Robin D Harrington, David J Sims, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
Cancer Cell
|
November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Linda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Page
of 8